Table 1.
Sensitivity of H7 influenza viruses associated with disease in humans in the NA inhibition assay with MUNANAd substrate
| Virusa | Subtypeb | Patient symptom(s)a | Mean IC50 ± SD (nM)c |
||
|---|---|---|---|---|---|
| Zanamivir | Oseltamivir carboxylate | Peramivir | |||
| A/Netherlands/219/2003 | HPAI H7N7 | Respiratory, fatal | 6.72 ± 0.97 | 3.28 ± 0.37 | 1.54 ± 0.01 |
| A/Netherlands/230/2003 | HPAI H7N7 | Conjunctivitis | 3.36 ± 0.42 | 1.05 ± 0.05 | 0.62 ± 0.09 |
| A/Canada/504/2004 | HPAI H7N3 | Conjunctivitis | 2.95 ± 0.16 | 1.64 ± 0.22 | 1.32 ± 0.15 |
| A/Canada/444/2004 | LPAI H7N3 | Conjunctivitis | 3.41 ± 0.13 | 2.05 ± 0.11 | 1.56 ± 0.04 |
| A/New York/107/2003 | LPAI H7N2 | Respiratory | 2.58 ± 0.33 | 0.55 ± 0.06 | 0.76 ± 0.11 |
a
Source information for clinical isolates and patient information was published previously (3, 10, 25). Identical virus stocks were used for in vitro and in vivo experiments.
b
HPAI, highly pathogenic avian influenza virus; LPAI, low-pathogenicity avian influenza virus.
c
Mean IC50 ± standard deviation (SD) values were calculated from data collected from duplicate independent experiments.
d
MUNANA, 2′-(4-methylumbelliferyl)-α-d-N-acetylneuraminic acid.